This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Implantable cardioverter defibrillators

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • this is a treatment that can detect a life-threatening arrythmia (e.g. ventricular fibrillation) and restore the patient to normal rhythm
  • efficacy:
    • there have been a number of randomised studies that have provided evidence of life-saving efficacy of the ICD, with reductions of overall mortality of 20-54% compared to anti-arrhythmic drugs (1)
    • ICD therapy is effective in primary and secondary prevention of sudden cardiac death among patients with prior myocardial infarction and depressed ejection fraction
    • ICD therapy appears to significantly reduce mortality in patients with nonischaemic cardiomyopathy (2)

Reference:

  1. British Heart Foundation, Factfile 5/99.
  2. Desai AS et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA 2004;292:2874-9

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.